The 19 restricted peptides spanned nearly every major clinical category in peptide therapy: tissue repair (BPC-157, Thymosin Beta-4), immune modulation (Thymosin Alpha-1, Selank), growth hormone signaling (CJC-1295, Ipamorelin, GHRP-2, GHRP-6), metabolic support (AOD-9604, MOTS-C), cognitive health (Semax, Selank), wound healing (GHK-Cu), and others including KPV, Kisspeptin-10, Melanotan II, PEG-MGF, Epitalon, Cathelicidin LL-37, and Emideltide (DSIP)
A multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial (EudraCT 2007-0006731-31, NCT00777140) evaluated the safety, tolerability, and potential efficacy of DFO in patients with acute ischemic stroke in the middle cerebral artery region
APC is already reviewing the proposal and will be submitting comments
During the Treatment: Peptides are administered using tiny, nearly painless injections or capsules